Clinical Trial Update: Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating switching virologically suppressed adults aged 60+ from TDF-containing regimens to the single-tablet regimen E/C/F/TAF; study completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide fixed-dose combination

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1 Infection | Phase 3 | Status: COMPLETED | Results posted: 2019-02-19